A new oral drug called daraxonrasib nearly doubled overall survival time for patients with advanced pancreatic cancer compared to standard chemotherapy [1].
This development represents a significant shift in treating one of the most lethal forms of cancer, as the drug provides a targeted oral alternative to invasive chemotherapy treatments.
Researchers presented the findings this week at the American Society of Clinical Oncology (ASCO) conference in Chicago [2]. The treatment specifically targets the KRAS G12D mutation, a genetic driver that fuels the growth of pancreatic tumors [3].
The clinical trial enrolled 168 patients with RAS-mutated pancreatic cancer [4]. While some reports describe the study as a first-in-human trial and others identify it as a Phase 3 clinical trial [4, 5], the data indicates that survival time was roughly two times longer for those taking the pill than for those receiving standard chemotherapy [1].
Pancreatic cancer remains exceptionally difficult to treat once it reaches advanced or metastatic stages. Current data shows that 97% of patients with advanced pancreatic cancer die within five years [6]. By targeting the specific mutation driving the disease, daraxonrasib aims to disrupt the cellular mechanisms that allow these tumors to proliferate.
The daily pill offers a less toxic administration route than traditional chemotherapy, which often causes systemic illness. The ASCO presentation highlights a potential transition toward precision medicine in oncology, moving away from broad-spectrum poisons toward molecules designed for specific genetic markers [2].
“Survival time was roughly two times longer for those taking the pill than for those receiving standard chemotherapy.”
The success of daraxonrasib suggests that targeting the KRAS G12D mutation is a viable pathway for improving outcomes in pancreatic cancer, a disease historically resistant to most therapies. If these results hold across larger populations, it could shift the standard of care from general chemotherapy to targeted oral therapies, significantly reducing patient morbidity and extending life expectancy for those with specific genetic mutations.
